Proteome Profiling in Murine Models of Multiple Sclerosis: Identification of Stage Specific Markers and Culprits for Tissue Damage
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The identification of new biomarkers is of high interest for the prediction of the disease course and also for the identification of pathomechanisms in multiple sclerosis (MS). To specify markers of the chronic disease phase, we performed proteome profiling during the later phase of myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis (MOG-EAE, day 35 after immunization) as a model disease mimicking many aspects of secondary progressive MS. In comparison to healthy controls, high resolution 2 dimensional gel electrophoresis revealed a number of regulated proteins, among them glial fibrilary acidic protein (GFAP). Phase specific up-regulation of GFAP in chronic EAE was confirmed by western blotting and immunohistochemistry. Protein levels of GFAP were also increased in the cerebrospinal fluid of MS patients with specificity for the secondary progressive disease phase. In a next step, proteome profiling of an EAE model with enhanced degenerative mechanisms revealed regulation of alpha-internexin, syntaxin binding protein 1, annexin V and glutamate decarboxylase in the ciliary neurotrophic factor (CNTF) knockout mouse. The identification of these proteins implicate an increased apoptosis and enhanced axonal disintegration and correlate well the described pattern of tissue injury in CNTF -/- mice which involve oligodendrocyte (OL) apoptosis and axonal injury.In summary, our findings underscore the value of proteome analyses as screening method for stage specific biomarkers and for the identification of new culprits for tissue damage in chronic autoimmune demyelination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk Alleles for Multiple Sclerosis Identified by a Genomewide Study
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa073493 · Cited by 1,746 · cited 1×
“Screening for polymorphisms associated with disease progression led to the identification of variations in the gene of the signaling molecule PD1 as genetic modifier [11] and a genome wide association studies identified the IL2RA and IL7RA as risk factors for MS [12].”
BackgroundGold, R. (2006) · Brain · doi:10.1093/brain/awl075 · Cited by 1,017 · cited 2×
“In particular, stage specific EAE models [19] may indicate which molecule bears the highest level of success as biomarker for disease progression not only for EAE itself, but possibly also for MS.”
BackgroundSelf-citationA longitudinal study of abnormalities on MRI and disability from multiple sclerosis
Brex, P. A., Ciccarelli, O., O'Riordan, J. I., Sailer, M., Thompson, A. J., & Miller, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011341 · Cited by 861
Liedtke, W., Edelmann, W., Bieri, P. L., Chiu, F.-C., Cowan, N. J., Kucherlapati, R., & Raine, C. S. (1996) · Neuron · doi:10.1016/s0896-6273(00)80194-4 · Cited by 538
Cited by
Serum GFAP as a biomarker for disease severity in multiple sclerosis
Abdelhak, A., Huss, A., Kassubek, J., Tumani, H., & Otto, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-33158-8 · Cited by 291
Self-citationNeurofilament Proteins as Biomarkers to Monitor Neurological Diseases and the Efficacy of Therapies
Yuan, A., & Nixon, R. A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.689938 · Cited by 290
Ten years of proteomics in multiple sclerosis
Farias, A. S., Pradella, F., Schmitt, A., Santos, L. M. B., & Martins‐de‐Souza, D. (2014) · PROTEOMICS · doi:10.1002/pmic.201300268 · Cited by 40
Sen, M. K., Almuslehi, M. S. M., Gyengesi, E., Myers, S. J., Shortland, P. J., Mahns, D. A., & Coorssen, J. R. (2019) · Cells · doi:10.3390/cells8111314 · Cited by 35
Almuslehi, M. S. M., Sen, M. K., Shortland, P. J., Mahns, D. A., & Coorssen, J. R. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-022-01997-w · Cited by 12
“In part, this similarity is likely attributable to the large number (15) of proteomic studies carried out using the EAE model (Alt et al., 2005; Dagley et al., 2014; Farias et al., 2012; Fazeli et al., 2013; Fazeli et al., 2010; Gonzalez et al., 2019; Hasan et al., 2019; Jain et al., 2009; Jain et al., 2012; Jastorff…”
MethodResult
Metadata
- Authors
- Linker, R. A., Brechlin, P., Jesse, S., Steinacker, P., Lee, D. H., Asif, A. R., Jahn, O., Tumani, H., Gold, R., & Otto, M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-10-28
- Volume
- 4
- Issue
- 10
- Pages
- e7624
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2062128157
- Cited by
- 49
- References
- 4
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Proteome Profiling in Murine Models of Multiple Sclerosis: Identification of Stage Specific Markers and Culprits for Tissue Damage. https://app.cochat.ai/papers/10.1371/journal.pone.0007624
- The paper
- Linker, R. A., Brechlin, P., Jesse, S., Steinacker, P., Lee, D. H., Asif, A. R., Jahn, O., Tumani, H., Gold, R., & Otto, M. (2009). Proteome Profiling in Murine Models of Multiple Sclerosis: Identification of Stage Specific Markers and Culprits for Tissue Damage. PLoS ONE. https://doi.org/10.1371/journal.pone.0007624
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.